首页 > 市场调查报告书 > 医疗设备

伤口护理

市场调查报告书

商品编码

1542953

全球伤口冲洗系统市场 - 2024-2031

Global Wound Irrigation System Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球伤口冲洗系统市场在2023年达到2.83亿美元，预计到2031年将达到3.7295亿美元，在2024-2031年预测期间复合年增长率为3.6%。

伤口冲洗系统被描述为溶液流过暴露的断裂表面，以减少微生物定植，并去除明显的异物颗粒和伤口渗出物。伤口冲洗（即在伤口闭合前冲洗伤口）旨在透过在部位闭合前清除手术区域的组织碎片、代谢废物和组织渗出物来减少微生物负荷。当伤口冲洗正确时，可以加快癒合过程并降低併发症的风险。

唯一应该避免冲洗的伤口是那些正在流血的伤口。冲洗的主要优点是它有助于维持健康、湿润的环境，有助于清洁、协助清创并改善伤口癒合过程。如果操作正确，可以减少伤口癒合的时间，并有助于减少疤痕。由于伤口冲洗相当简单，因此无论您在哪里，无论伤口位于何处，都可以轻鬆进行。

市场动态：

司机

慢性伤口的盛行率不断增加

全球伤口冲洗系统市场的需求由多种因素所驱动。慢性伤口盛行率的上升推动了市场的成长。

此外，近年来外科手术的增加将推动该市场的需求。伤口冲洗系统在各种外科手术中扮演着非常重要的角色。 60岁以上老年人口的增加也是推动因素之一。该领域的技术进步也是伤口冲洗系统市场的主要驱动因素之一。

慢性伤口是指那些没有透过正常、有序和及时的修復过程进展的伤口。例如，根据 Wounds International 发布的一篇文章，根据一项估计，2023 年 12 月，7,700 万名糖尿病患者中，25% 患有糖尿病足溃疡。静脉溃疡是下肢慢性静脉功能不全最严重、最令人衰弱的结果，占下肢溃疡的80%。印度慢性伤口的盛行率估计为每 1,000 人 4.5 人。

根据 facs.org 估计，已开发国家有 1% 到 2% 的人口一生中会遭受慢性伤口的困扰。据国际糖尿病联盟称，全球成年人口（20 - 79 岁）的 10.5% 估计患有糖尿病，而几乎一半的人不知道自己患有糖尿病。

限制

先进伤口系统的高成本、发展中国家的可用性有限以及感染引起的危害等因素预计将阻碍市场的发展。

细分市场分析

全球伤口冲洗系统市场根据产品类型、应用、最终用户和地区进行细分。

慢性伤口细分市场约占全球伤口冲洗系统市占率的44.1%

预计慢性伤口细分市场将在预测期内占据最大的市场份额。在这一领域，政府监管的发展和慢性伤口冲洗技术的进步将推动该市场的发展。

由于全球人口慢性病的增加，近年来慢性伤口也增加。据 nih.gov 称，腿部静脉溃疡是一项重大的临床挑战，它们是慢性静脉功能不全 (CVI) 和静脉高压的结果。三个月的治愈率估计为 40%，一旦治愈，高达 80% 的患者会在 3 个月内復发。据通报，VLU 的盛行率约为 1.08%，发生率高达 1.33%。 VLU 的盛行率和发生率随着年龄的增长而增加。

压疮是由于压力或压力与剪切力相结合造成的皮肤和/或皮下组织的局部损伤，通常位于骨突出处。据估计，美国约有 250 万人因压疮住院。在英国，总治疗费用的 4% 用于治疗压疮。除了治疗压疮的额外费用外，还有床位预约和住院产生的相关费用。这些溃疡也导致护理人员工作量增加50%

市场地域占有率

北美约占全球伤口冲洗系统市占率的46.3%

预计北美地区将在预测期内占据最大的市场份额。慢性伤口发生率的上升、人们意识的增强以及政府在该地区分配的资金有助于推动市场的发展。

根据 facs.org 报导，据报道，在美国，慢性伤口影响着约 650 万名患者。美国政府为伤口护理拨出了巨额资金。慢性伤口对社会带来的经济负担是巨大的。在美国，医疗保健系统每年花费超过 250 亿美元用于治疗伤口相关併发症。慢性伤口影响着美国近 2.5% 人口的生活品质。这个比例在老年人中较大。这些伤口可能会导致一系列併发症和医疗费用。

北美地区的技术进步是其市场份额最大的原因之一。美国医疗保险和医疗补助服务中心提议修订其当地承保决定，限制在美国医疗保险人群中使用皮肤替代移植物/细胞和/或基于组织的产品来治疗糖尿病足溃疡和静脉性腿部溃疡。

美国食品药物管理局 (FDA) 重新将重点放在解决不癒合慢性伤口上，并概述了解决不癒合慢性伤口产品开发中已识别障碍的努力。新方法强调让关键的伤口癒合利益相关者参与进来，包括学术界、专业协会、病患团体、报销组织和产业。最后，最近的进展表明，由于屏障功能恢復方面的缺陷，根据目前 FDA 伤口闭合定义闭合的伤口可能仍保持功能开放，因此需要重新审视伤口闭合终点。

A Wound Irrigation system is described as the flow of a solution through an exposed fracture surface to reduce microbial colonization, to remove apparent foreign particles and wound exudates. Wound irrigation, that is washing out a wound before wound closure) aims to reduce the microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field before site closure. When wound irrigation is done correctly, it speeds up the healing process and reduces the risk of complications.

The only types of wounds that you should avoid irrigating are those that are actively bleeding. The primary advantages of irrigation are that it helps keep a healthy, moist environment that's conducive to cleaning, assists debridement, and improves the wound healing process. When done correctly, it reduces the amount of time a wound takes to heal and can help minimize scarring. Since wound irrigation is fairly straightforward, it's easy to perform anywhere you are, regardless of the location of your wound.

Market Dynamics: Drivers

Increasing prevalence of chronic wounds

The demand for the global wound irrigation system market is driven by multiple factors. The rising prevalence of chronic wounds propels the market growth.

Furthermore, the demand for this market will be fueled by the increase in surgical procedures in recent times. The wound irrigation system plays a very vital role in various surgical procedures. The increase in the population of older people who are 60 years and above is also one of the driving factors. Technological advancements in this field are also one of the major driving factors in the wound irrigation system market.

Chronic wounds are those that do not progress through a normal, orderly, and timely sequence of repair. For instance, according to an article posted by Wounds International, in December 2023, according to one estimate, out of 77 million individuals with diabetes, 25% develop a diabetic foot ulcer. Venous ulcers are the most severe and debilitating outcome of chronic venous insufficiency in the lower limbs, accounting for 80% of lower-extremity ulcerations. The prevalence of chronic wounds in India is estimated to be 4.5 per 1,000 people.

According to facs.org, it is estimated that 1 to 2 percent of the population in developed countries will suffer from a chronic wound in their lifetime. According to the International Diabetes Federation, 10.5% of the adult global population (20 - 79 years) is estimated to have diabetes with almost half of the people being unaware of it.

Restraints

Factors such as high cost associated with advanced wound systems, limited availability in developing countries, and hazards caused due to infection are expected to hamper the market.

Market Segment Analysis

The global wound irrigation system market is segmented based on product type, application, end-user, and region.

The segment chronic wounds accounted for approximately 44.1% of the global wound irrigation system market share

The chronic wounds segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and technological advancements for chronic wound irrigation would drive this market.

Due to the increase in chronic diseases in the global population, there has been an increase in chronic wounds in recent times. According to nih.gov, venous leg ulcers are a major clinical challenge they are the result of chronic venous insufficiency(CVI) and venous hypertension. Their three-month healing rate is estimated at 40 %and once healed up to 80% of patients develop a recurrence within 3 months. The prevalence of VLUs is reported around 1.08% and the incidence is up to 1.33%. The prevalence and incidence of VLU increase with age.

Pressure Ulcer is a localized injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear. It is estimated that about 2.5 million hospitalizations in the United States are due to pressure ulcers. In the UK, 4% of the total treatment costs are allocated for the treatment of pressure ulcers. In addition to the extra costs spent on the treatment of pressure ulcers, there are bed reservations and associated costs arising from hospitalization. These ulcers also cause the nursing staff an increase in workload by 50%

Market Geographical Share

North America accounted for approximately 46.3% of the global wound irrigation system market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic wounds, growing awareness among people, and the funding allotted by the government in this region help to propel the market.

According to facs.org, In the United States, it is reported that chronic wounds affect approximately 6.5 million patients. The US government allotted a very hefty funding regarding wound care. The financial burden imposed by chronic wounds on society is substantial. In the United States, more than $25 billion is spent by the healthcare system on treating wound-related complications per year. Chronic wounds impact the quality of life of nearly 2.5% of the total population of the United States. This fraction is larger in the elderly. These wounds can lead to a range of complications and healthcare costs.

The technological advancements in the region of North America are one of the reasons for the largest market share. The U.S. Centers for Medicare and Medicaid Services had proposed a revision of its local coverage determination limiting the use of skin substitute grafts/cellular and/or tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the U.S. Medicare population.

The U.S. Food and Drug Administration (FDA) has renewed its focus on addressing non-healing chronic wounds and has outlined efforts to address identified barriers to product development for non-healing chronic wounds. The new approach emphasizes engaging key wound-healing stakeholders, including academia, professional associations, patient groups, reimbursement organizations, and industry. Finally, recent advances demonstrating that wounds closed by the current FDA definition of wound closure may remain functionally open because of deficiencies in the restoration of barrier function warrant revisiting the wound closure endpoint.

Market Segmentation

By Product Type

Manual Operated
Syringe Based
Spray Based
Nozzle Based
Battery Operated

By Application

Acute Wounds
Surgical Wounds
Traumatic Wounds
Burnt Wounds
Chronic Wounds
Diabetic foot Ulcers
Venous Ulcers
Pressure Ulcers
Others

By End-User

Hospitals
Ambulatory Surgical Centre
Homecare
Academic and Research Institutes
Others

By Region

North America
The U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the global wound irrigation system market include Zimmer Biomet, Stryker Corporation, Bionix Llc., Irrimax Corporation, Cooper Surgical Inc., Westmed Inc., Becton Dickson and Company, Essity Health & Medical, Centurion Service Group, and Hopkins Medical Products among others.

Key Developments

In June 2021, Irrimax Corporation, manufacturer of irrisept, announced new clearance from the U.S. Food and Drug Administration (FDA), making irrisept the only self-contained irrigation system for antimicrobial wound lavage in the U.S. market. Today, more than 2,000 U.S. hospitals are using the irrisept product totaling more than 2 million lifetime uses.
In April 2021, the FDA notified that Zimmer Biomet's single-step application wound irrigation solution, XPERIENCE No Rinse Antimicrobial Solution, has been cleared in the U.S. for immediate distribution. The device was originally submitted to the FDA as MIS Solution but is now being marketed as XPERIENCE.
In May 2021, BD (Becton, Dickinson, and Company) a leading global medical technology company, announced today the availability of BD Surgiphor(TM) Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris.

Why Purchase the Report?

To visualize the global wound irrigation system market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global wound irrigation system market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Chronic Wounds
  - 4.1.1.2. Increase in Surgical Procedures
  - 4.1.1.3. Increase in population of older people
  - 4.1.1.4. Technological Advancements
4.2. Restraints
- 4.2.1. High Cost of Advanced Wound Irrigation Systems
- 4.2.2. Limited Accessibility in Developing Regions
4.3. Opportunity
4.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Manual Operated*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Battery Operated

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Acute Wounds *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chronic Wounds
7.4. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Homecare
8.5. Academic and Research Centers
8.6. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Zimmer Biomet *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Striker Corporation
11.3. Bionix Llc.
11.4. Irrimax Corporation
11.5. Cooper Surgical Inc.
11.6. Westmed Inc.
11.7. Becton Dickson and Company
11.8. Essity Health & Medical
11.9. Centurion Service Group
11.10. Hopkins Medical Products (*LIST NOT EXHAUSTIVE)